Embed Size (px)
Citation preview
Rimonabant in Obesity Rimonabant in Obesity Rimonabant in Obesity Rimonabant in Obesity
Presented atPresented atAmerican College of CardiologyAmerican College of Cardiology
Scientific Sessions 2004Scientific Sessions 2004
Presented by Dr. Jean-Pierre Despres Presented by Dr. Jean-Pierre Despres
RIO LIPIDS TrialRIO LIPIDS TrialRIO LIPIDS TrialRIO LIPIDS Trial
www. Clinical trial results.org
RimonabantA selective cannabinoid type 1
receptor antagonist
5 mg n=345
RimonabantA selective cannabinoid type 1
receptor antagonist
5 mg n=345
Endpoints (1 year): Weight loss 5% of body weight and 10% of body weight Change in lipid profile
Endpoints (1 year): Weight loss 5% of body weight and 10% of body weight Change in lipid profile
RIO LIPIDS TrialRIO LIPIDS TrialRIO LIPIDS TrialRIO LIPIDS Trial
Presented at ACC Scientific Sessions 2004Presented at ACC Scientific Sessions 2004
1,036 patients with abdominal obesity and
abnormal lipid profiles
Randomized, double-blind, multicenter
1,036 patients with abdominal obesity and
abnormal lipid profiles
Randomized, double-blind, multicenter
Placebo n=342
Placebo n=342
Rimonabant A selective cannabinoid type 1
receptor antagonist
20 mg n=346
Rimonabant A selective cannabinoid type 1
receptor antagonist
20 mg n=346
Treatment for 1 YearTreatment for 1 Year
www. Clinical trial results.org
RIO LIPIDS Trial RIO LIPIDS Trial RIO LIPIDS Trial RIO LIPIDS Trial
58.4%
30.0%
19.5%
0%
20%
40%
60% Rimonabant 20 mg
Rimonabant 5 mg
Placebo
58.4%
30.0%
19.5%
0%
20%
40%
60% Rimonabant 20 mg
Rimonabant 5 mg
Placebo
Weight Loss 5%p < 0.001 for high-dose vs placebo
Presented at ACC Scientific Sessions 2004Presented at ACC Scientific Sessions 2004
Weight Loss 10%p < 0.001 for high-dose vs placebo
32.6%
10.6%
7.2%
0%
20%
40%
32.6%
10.6%
7.2%
0%
20%
40%
www. Clinical trial results.org
RIO LIPIDS Trial RIO LIPIDS Trial RIO LIPIDS Trial RIO LIPIDS Trial
Relative Reduction in CRP p=0.007 for rimonabant 20 mg vs placebo
27.0%
11.0%
0%
10%
20%
30%
Rimonabant 20 mg Placebo
27.0%
11.0%
0%
10%
20%
30%
Rimonabant 20 mg Placebo
• C-reactive protein reduction greater in rimonabant 20 mg arm compared with placebo (from 3.7 to 2.7 mg/l with rimonabant 20 mg vs. 3.6 to 3.2 mg/l with placebo, p=0.007)
• HDL increased 23% and triglycerides decreased 15% in rimonabant 20 mg, but no significant difference in LDL levels
Presented at ACC Scientific Sessions 2004Presented at ACC Scientific Sessions 2004
www. Clinical trial results.org
RIO LIPIDS Trial RIO LIPIDS Trial RIO LIPIDS Trial RIO LIPIDS Trial
• Among patients with abdominal obesity and abnormal lipid profiles, use of the selective cannabinoid type 1 receptor antagonist rimonabant in a 5 mg or 20 mg dose was associated with greater weight reduction after 1 year of treatment compared with placebo
• Additional benefits were observed in HDL and triglyceride levels with rimonabant
• Obesity is a growing epidemic, which has been shown to contribute to a variety of co-morbidities, including increased coronary heart disease, diabetes, and hyperlipidemia
• Few pharmacologic agents have been identified as both safe and effective in reducing weight, pointing to the potential importance of the present study
• Further evaluation is warranted
• Among patients with abdominal obesity and abnormal lipid profiles, use of the selective cannabinoid type 1 receptor antagonist rimonabant in a 5 mg or 20 mg dose was associated with greater weight reduction after 1 year of treatment compared with placebo
• Additional benefits were observed in HDL and triglyceride levels with rimonabant
• Obesity is a growing epidemic, which has been shown to contribute to a variety of co-morbidities, including increased coronary heart disease, diabetes, and hyperlipidemia
• Few pharmacologic agents have been identified as both safe and effective in reducing weight, pointing to the potential importance of the present study
• Further evaluation is warranted
